Related Experiment Video
Updated: Aug 16, 2026
Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Diamond-Blackfan anemia
L Da Costa1, T N Willig, J Fixler
1Lawrence Berkeley National Laboratory, California 94720, USA. ldacosta@lbl.gov
Insights
Diamond-Blackfan Anemia (DBA) is a rare congenital anemia. Genetic defects, including RPS19 mutations, cause DBA, but other genetic factors are involved.
Area of Science:
- Hematology
- Genetics
- Pediatrics
Background:
- Diamond-Blackfan Anemia (DBA) is a rare congenital hypoplastic anemia.
- It presents with severe anemia and erythroblastopenia in normocellular bone marrow.
- Developmental abnormalities occur in 40% of affected infants.
Purpose of the Study:
- To summarize the current understanding of Diamond-Blackfan Anemia.
- To highlight the genetic basis and ongoing research into DBA pathogenesis.
Main Methods:
- Review of existing literature on Diamond-Blackfan Anemia.
- Analysis of molecular studies identifying genetic mutations and loci.
- Discussion of clinical presentation and treatment response.
Main Results:
- DBA is characterized by aregenerative anemia and erythroblastopenia.
- Mutations in the RPS19 gene are found in 25% of DBA patients.
- DBA is also linked to a locus on chromosome 8p, with other genetic causes yet to be identified.
Conclusions:
- While steroid therapy benefits many, the genetic underpinnings of DBA are complex and not fully defined.
- Further molecular studies are crucial for a comprehensive understanding of DBA pathogenesis.
- Identifying novel genetic defects will advance DBA diagnosis and treatment.
Abstract:
Diamond-Blackfan Anemia (DBA) is a rare, congenital hypoplastic anemia often diagnosed early in infancy. A moderate to severe aregenerative anemia is found in association with erythroblastopenia in an otherwise normocellular bone marrow. In 40% of these infants with DBA, diverse developmental abnormalities are also noted. A majority of patients with DBA respond to steroid therapy. Recent molecular studies have identified mutations in the gene encoding the ribosomal protein RPS19 on chromosome 19 in 25% of patients with DBA. In another subset of patients, linkage analysis has identified another locus on chromosome 8p in association with DBA. There are, however, other cases of DBA that are linked neither to the RPS19 gene nor to the locus on 8p, implying the involvement of yet-to-be-defined genetic defects in the cause of DBA. The pathogenesis of DBA is still to be fully defined and it is anticipated that further molecular studies will lead to a better understanding of this complex disease.
Related Concept Videos
01:14Erythropoiesis
01:27Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
01:24Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...